Literature DB >> 21441574

Multiple myeloma treatment strategies with novel agents in 2011: a European perspective.

Heinz Ludwig1, Meral Beksac, Joan Bladé, Jamie Cavenagh, Michele Cavo, Michel Delforge, Meletios Dimopoulos, Johannes Drach, Hermann Einsele, Thierry Facon, Hartmut Goldschmidt, Jean-Luc Harousseau, Urs Hess, Martin Kropff, Fernando Leal da Costa, Vernon Louw, Hila Magen-Nativ, Larisa Mendeleeva, Hareth Nahi, Torben Plesner, Jesús San-Miguel, Pieter Sonneveld, Miklos Udvardy, Pia Sondergeld, Antonio Palumbo.   

Abstract

The arrival of the novel agents thalidomide, bortezomib, and lenalidomide has significantly changed our approach to the management of multiple myeloma and, importantly, patient outcomes have improved. These agents have been investigated intensively in different treatment settings, providing us with data to make evidence-based decisions regarding the optimal management of patients. This review is an update to a previous summary of European treatment practices that examines new data that have been published or presented at congresses up to the end of 2010 and assesses their impact on treatment practices.

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21441574      PMCID： PMC3228121          DOI： 10.1634/theoncologist.2010-0386

Source DB:  PubMed          Journal:  Oncologist        ISSN： 1083-7159


  50 in total

1.  Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study.

Authors:  Michele Cavo; Paola Tacchetti; Francesca Patriarca; Maria Teresa Petrucci; Lucia Pantani; Monica Galli; Francesco Di Raimondo; Claudia Crippa; Elena Zamagni; Antonio Palumbo; Massimo Offidani; Paolo Corradini; Franco Narni; Antonio Spadano; Norbert Pescosta; Giorgio Lambertenghi Deliliers; Antonio Ledda; Claudia Cellini; Tommaso Caravita; Patrizia Tosi; Michele Baccarani
Journal:  Lancet       Date:  2010-12-09       Impact factor: 79.321

Review 2.  Treatment-related peripheral neuropathy in multiple myeloma: the challenge continues.

Authors:  Michel Delforge; Joan Bladé; Meletios A Dimopoulos; Thierry Facon; Martin Kropff; Heinz Ludwig; Antonio Palumbo; Philip Van Damme; Jesús F San-Miguel; Pieter Sonneveld
Journal:  Lancet Oncol       Date:  2010-11       Impact factor: 41.316

3.  Major tumor shrinking and persistent molecular remissions after consolidation with bortezomib, thalidomide, and dexamethasone in patients with autografted myeloma.

Authors:  Marco Ladetto; Gloria Pagliano; Simone Ferrero; Federica Cavallo; Daniela Drandi; Loredana Santo; Claudia Crippa; Luca De Rosa; Patrizia Pregno; Mariella Grasso; Anna Marina Liberati; Tommaso Caravita; Francesco Pisani; Tommasina Guglielmelli; Vincenzo Callea; Pellegrino Musto; Clotilde Cangialosi; Roberto Passera; Mario Boccadoro; Antonio Palumbo
Journal:  J Clin Oncol       Date:  2010-03-22       Impact factor: 44.544

4.  Efficacy and safety of once-weekly bortezomib in multiple myeloma patients.

Authors:  Sara Bringhen; Alessandra Larocca; Davide Rossi; Maide Cavalli; Mariella Genuardi; Roberto Ria; Silvia Gentili; Francesca Patriarca; Chiara Nozzoli; Anna Levi; Tommasina Guglielmelli; Giulia Benevolo; Vincenzo Callea; Vincenzo Rizzo; Clotilde Cangialosi; Pellegrino Musto; Luca De Rosa; Anna Marina Liberati; Mariella Grasso; Antonietta P Falcone; Andrea Evangelista; Michele Cavo; Gianluca Gaidano; Mario Boccadoro; Antonio Palumbo
Journal:  Blood       Date:  2010-08-31       Impact factor: 22.113

5.  Phase III study of the value of thalidomide added to melphalan plus prednisone in elderly patients with newly diagnosed multiple myeloma: the HOVON 49 Study.

Authors:  Pierre Wijermans; Martijn Schaafsma; Fabian Termorshuizen; Rianne Ammerlaan; Shulamiet Wittebol; Harm Sinnige; Sonja Zweegman; Marinus van Marwijk Kooy; René van der Griend; Henk Lokhorst; Pieter Sonneveld
Journal:  J Clin Oncol       Date:  2010-06-01       Impact factor: 44.544

6.  Long-term follow-up of autotransplantation trials for multiple myeloma: update of protocols conducted by the intergroupe francophone du myelome, southwest oncology group, and university of arkansas for medical sciences.

Authors:  Bart Barlogie; Michel Attal; John Crowley; Frits van Rhee; Jackie Szymonifka; Philippe Moreau; Brian G M Durie; Jean-Luc Harousseau
Journal:  J Clin Oncol       Date:  2010-01-19       Impact factor: 44.544

7.  The efficacy and safety of lenalidomide plus dexamethasone in relapsed and/or refractory multiple myeloma patients with impaired renal function.

Authors:  Meletios Dimopoulos; Adrian Alegre; Edward A Stadtmauer; Hartmut Goldschmidt; Jeffrey A Zonder; Carlos M de Castro; Zvenyslava Masliak; Donna Reece; Marta Olesnyckyj; Zhinuan Yu; Donna M Weber
Journal:  Cancer       Date:  2010-08-15       Impact factor: 6.860

8.  Lenalidomide plus dexamethasone is more effective than dexamethasone alone in patients with relapsed or refractory multiple myeloma regardless of prior thalidomide exposure.

Authors:  Michael Wang; Meletios A Dimopoulos; Christine Chen; M Teresa Cibeira; Michel Attal; Andrew Spencer; S Vincent Rajkumar; Zhinuan Yu; Marta Olesnyckyj; Jerome B Zeldis; Robert D Knight; Donna M Weber
Journal:  Blood       Date:  2008-09-17       Impact factor: 22.113

9.  Prediction of survival in multiple myeloma based on gene expression profiles reveals cell cycle and chromosomal instability signatures in high-risk patients and hyperdiploid signatures in low-risk patients: a study of the Intergroupe Francophone du Myélome.

Authors:  Olivier Decaux; Laurence Lodé; Florence Magrangeas; Catherine Charbonnel; Wilfried Gouraud; Pascal Jézéquel; Michel Attal; Jean-Luc Harousseau; Philippe Moreau; Régis Bataille; Loïc Campion; Hervé Avet-Loiseau; Stéphane Minvielle
Journal:  J Clin Oncol       Date:  2008-06-30       Impact factor: 44.544

Review 10.  Current multiple myeloma treatment strategies with novel agents: a European perspective.

Authors:  Heinz Ludwig; Meral Beksac; Joan Bladé; Mario Boccadoro; Jamie Cavenagh; Michele Cavo; Meletios Dimopoulos; Johannes Drach; Hermann Einsele; Thierry Facon; Hartmut Goldschmidt; Jean-Luc Harousseau; Urs Hess; Nicolas Ketterer; Martin Kropff; Larisa Mendeleeva; Gareth Morgan; Antonio Palumbo; Torben Plesner; Jesús San Miguel; Ofer Shpilberg; Pia Sondergeld; Pieter Sonneveld; Sonja Zweegman
Journal:  Oncologist       Date:  2010-01-19
View more
  9 in total

1.  Health care costs and resource utilization, including patient burden, associated with novel-agent-based treatment versus other therapies for multiple myeloma: findings using real-world claims data.

Authors:  April Teitelbaum; Abbie Ba-Mancini; Hui Huang; Henry J Henk
Journal:  Oncologist       Date:  2013-01-08

2.  The cost-effectiveness of initial treatment of multiple myeloma in the U.S. with bortezomib plus melphalan and prednisone versus thalidomide plus melphalan and prednisone or lenalidomide plus melphalan and prednisone with continuous lenalidomide maintenance treatment.

Authors:  Louis P Garrison; Si-Tien Wang; Hui Huang; Abbie Ba-Mancini; Hongliang Shi; Kristina Chen; Caroline Korves; Ravinder Dhawan; Andrew Cakana; Helgi van de Velde; Deyanira Corzo; Mei Sheng Duh
Journal:  Oncologist       Date:  2013-01-08

Review 3.  The European medicines agency review of pomalidomide in combination with low-dose dexamethasone for the treatment of adult patients with multiple myeloma: summary of the scientific assessment of the committee for medicinal products for human use.

Authors:  Zahra Hanaizi; Beatriz Flores; Robert Hemmings; Jorge Camarero; Arantxa Sancho-Lopez; Tomas Salmonson; Christian Gisselbrecht; Edward Laane; Francesco Pignatti
Journal:  Oncologist       Date:  2015-02-11

4.  Thalidomide maintenance therapy in Japanese myeloma patients: a multicenter, phase II clinical trial (COMET study).

Authors:  Hirokazu Murakami; Tetsuhiro Kasamatsu; Jun Murakami; Toru Kiguchi; Takeshi Kanematsu; Daisuke Ogawa; Hiroyuki Takamatsu; Hiroshi Handa; Shuji Ozaki; Hirokazu Miki; Takeshi Takahashi; Takaaki Takeo; Tatsuya Yamauchi; Takanobu Morishita; Hiroshi Kosugi; Kazuyuki Shimizu
Journal:  Int J Hematol       Date:  2019-01-31       Impact factor: 2.490

Review 5.  European perspective on multiple myeloma treatment strategies: update following recent congresses.

Authors:  Heinz Ludwig; Hervé Avet-Loiseau; Joan Bladé; Mario Boccadoro; Jamie Cavenagh; Michele Cavo; Faith Davies; Javier de la Rubia; Sosana Delimpasi; Meletios Dimopoulos; Johannes Drach; Hermann Einsele; Thierry Facon; Hartmut Goldschmidt; Urs Hess; Ulf-Henrik Mellqvist; Philippe Moreau; Jesús San-Miguel; Pia Sondergeld; Pieter Sonneveld; Miklos Udvardy; Antonio Palumbo
Journal:  Oncologist       Date:  2012-05-09

6.  TRAP1 and the proteasome regulatory particle TBP7/Rpt3 interact in the endoplasmic reticulum and control cellular ubiquitination of specific mitochondrial proteins.

Authors:  M R Amoroso; D S Matassa; G Laudiero; A V Egorova; R S Polishchuk; F Maddalena; A Piscazzi; S Paladino; D Sarnataro; C Garbi; M Landriscina; F Esposito
Journal:  Cell Death Differ       Date:  2011-10-07       Impact factor: 15.828

7.  Design and rationale of FOCUS (PX-171-011): a randomized, open-label, phase 3 study of carfilzomib versus best supportive care regimen in patients with relapsed and refractory multiple myeloma (R/R MM).

Authors:  Roman Hájek; Richard Bryce; Sunhee Ro; Barbara Klencke; Heinz Ludwig
Journal:  BMC Cancer       Date:  2012-09-19       Impact factor: 4.430

8.  The therapeutic human CD38 antibody daratumumab improves the anti-myeloma effect of newly emerging multi-drug therapies.

Authors:  M S van der Veer; M de Weers; B van Kessel; J M Bakker; S Wittebol; P W H I Parren; H M Lokhorst; T Mutis
Journal:  Blood Cancer J       Date:  2011-10-28       Impact factor: 11.037

9.  Real-World Treatment Patterns, Outcomes, and Healthcare Resource Utilization in Relapsed or Refractory Multiple Myeloma: Evidence from a Medical Record Review in France.

Authors:  Huamao Mark Lin; Keith L Davis; James A Kaye; Katarina Luptakova; Saurabh P Nagar; Mohamad Mohty
Journal:  Adv Hematol       Date:  2019-01-29
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.